Newsletter
Sign up for the Fund's newsletter and get the lastest news about the Fund's investments.
Title Sort descending | Period | Programme | |
---|---|---|---|
Balancing the green transition and organisational resilience in SMEs | 2022 - 2025 | Industrial Researcher | |
Balancing the green transition and organisational resilience in SMEs
Period
2022 - 2025
Region
Region Hovedstaden Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
50.52 Invested
1.1 mill. Budget
2.1 mill. Partners
Aarhus University, Dansk Brand- og sikringsteknisk Institut People
Dansk Brand- og sikringsteknisk Institut
Read more about the project
| |||
BallastWISE system til analyse af levende organismer i ballastvand | 2017 - 2018 | Innobooster | |
BallastWISE system til analyse af levende organismer i ballastvand
Period
2017 - 2018
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
32.84 Invested
417.892 Budget
1.3 mill. Partners
MicroWISE People
MicroWise
Read more about the project
| |||
BaltVib | 2021 - 2023 | International collaborations | |
BaltVib
Period
2021 - 2023
Region
Program
Internationale samarbejder Area
Energi, Klima og Miljø Investment
Percentage
20.84 Invested
2.2 mill. Budget
10.8 mill. Partners
Leibniz Institute for Baltic Sea Research Warnemünde (IOW), Klaipeda University, National Marine Fisheries Research Institute, EEn University of Life Sciences, GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel, KTH Royal Institute of Technology, Abo Akademi University, KU People
Leibniz Institute for Baltic Sea Research Warnemünde (IOW)
Read more about the project
| |||
BAMPC EBM-001, an innovative Bispecific Antibody to treat Metastatic castration-resistant Prostate Cancer | 2023 - 2025 | Grand Solutions | |
BAMPC EBM-001, an innovative Bispecific Antibody to treat Metastatic castration-resistant Prostate Cancer
Period
2023 - 2025
Region
Program
Grand Solutions Area
Ikke defineret Investment
Percentage
74.51 Invested
12.3 mill. Budget
16.5 mill. Prostate cancer (PC), the second most common male cancer, affects 1.3 mil men and accounts for +360,000 deaths annually worldwide. At an early stage, local treatments (i.e. surgery, chemical castration and chemotherapy) often cure PC initially. However, an estimated 10-30% progress to metastatic castration-resistant PC (mCRPC) with no curative options, and 70% of patients with mCRPC die within 5 years. This highlights the need for more effective treatments such as immunotherapy with check point inhibitors that has shown remarkable clinical success with other cancer types but minimal efficacy in mCRPC due to the immunologically non-inflammatory nature of PC, characterised by restricted immune cell infiltration. Our approach addresses this unmet need through a bispecific monoclonal antibody, EBM-001, with specificity to Prostate-specific Membrane Antigen (PSMA) and IFNy which: 1) captures and accumulates the patient's own circulating IFNy from the blood: followed by 2) their redistribution to the site of the tumor, igniting an immunological activation by attracting the patient's immune cells to the cancer site. The unique mode of action of EBM-001, will enable a safe long lasting immune infiltration that will improve the efficacy of current immunotherapies for mCRPC.
Our consortium (Ebumab, Southern University of Denmark, Bioneer) will use this Grand Solutions project to advance EBM-001 from the current initial proof of concept, to provide in vivo PoC and CMC development.
Partners
Cymab ApS, University of Southern Denmark, Bioneer A/S People
Read more about the project
| |||
Banana Cph: InnoFounder Spring 2018 | 2018 - 2019 | Innofounder | |
Banana Cph: InnoFounder Spring 2018
Period
2018 - 2019
Region
Region Hovedstaden Program
Innofounder Area
Bioressourcer, Fødevarer og Livsstil Investment
Percentage
100 Invested
430.000 Budget
430.000 Partners
Banana Cph ApS People
Banana Cph ApS
Read more about the project
| |||
BandingMachine | 2018 - 2018 | Innobooster | |
BandingMachine
Period
2018 - 2018
Region
Region Midtjylland Program
Innobooster Area
Ikke defineret Investment
Percentage
29.45 Invested
430.017 Budget
1.5 mill. Partners
Mach-Tech A/S People
MACH-TECH A/S
Read more about the project
| |||
Banebrydende AI for radiologi til USA: Klinisk forskning og FDA-krav | 2022 - 2022 | Innobooster | |
Banebrydende AI for radiologi til USA: Klinisk forskning og FDA-krav
Period
2022 - 2022
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
1.0 mill. Budget
2.9 mill. Partners
Visiana ApS People
VISIANA ApS
Read more about the project
| |||
Banebrydende behandling til forebyggelse af alvorlig nedsat syn ved hornhindeløsning og andre relaterede øjensygdomme | 2018 - 2019 | Innobooster | |
Banebrydende behandling til forebyggelse af alvorlig nedsat syn ved hornhindeløsning og andre relaterede øjensygdomme
Period
2018 - 2019
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
33 Invested
495.000 Budget
1.5 mill. Partners
Københavns Universitet People
RetiCare IVS
Read more about the project
| |||
Banebrydende eventplatform skaber global standard for værdimåling af events, EventROE | 2018 - 2018 | Innobooster | |
Banebrydende eventplatform skaber global standard for værdimåling af events, EventROE
Period
2018 - 2018
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
25.74 Invested
448.000 Budget
1.7 mill. Partners
Tame ApS People
Tame ApS
Read more about the project
| |||
Banebrydende ny behandling til Cystisk Fibrose | 2017 - 2018 | Innobooster | |
Banebrydende ny behandling til Cystisk Fibrose
Period
2017 - 2018
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
32.28 Invested
485.536 Budget
1.5 mill. Partners
Unizyme Laboratories A/S People
UNIZYME LABORATORIES A/S
Read more about the project
| |||
Banebrydende teknologi giver rygpatienter nyt håb | 2020 - 2022 | Innobooster | |
Banebrydende teknologi giver rygpatienter nyt håb
Period
2020 - 2022
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
33 Invested
1.5 mill. Budget
4.7 mill. Partners
FBC Device ApS People
FBC DEVICE ApS
Read more about the project
| |||
Banebrydende teknologi til målinger af emissioner | 2023 - 2024 | Innofounder | |
Banebrydende teknologi til målinger af emissioner
Period
2023 - 2024
Region
Program
Innofounder Area
Ikke defineret Investment
Percentage
100 Invested
430.000 Budget
430.000 (af forretningsmæssige årsager er vi ikke interesseret i for meget offentlighed endnu)
Partners
CAT People
Read more about the project
| |||
Banebrydende termometer til mikrobølgeovn med store produktionsudfordringer | 2017 - 2017 | Innobooster | |
Banebrydende termometer til mikrobølgeovn med store produktionsudfordringer
Period
2017 - 2017
Region
Region Sjælland Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
495.000 Budget
1.5 mill. Partners
Senserna IVS People
Senserna A/S
Read more about the project
| |||
Banebrydende vinduesrobot med høj sikkerhed, kapacitet og effektivitet. | 2021 - 2022 | Innobooster | |
Banebrydende vinduesrobot med høj sikkerhed, kapacitet og effektivitet.
Period
2021 - 2022
Region
Region Midtjylland Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
349.800 Budget
1.1 mill. Partners
Smart Group ApS People
Smart Group ApS
Read more about the project
| |||
Bankruptcy Prediction using Natural Language Processing with Deep Learning | 2019 - 2022 | Industrial Researcher | |
Bankruptcy Prediction using Natural Language Processing with Deep Learning
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Handel, Service og Samfund Investment
Percentage
49.66 Invested
1.1 mill. Budget
2.2 mill. Partners
Copenhagen Business School, Nordea Danmark, Filial af Nordea Bank Abp, Finland People
Nordea Danmark, Filial af Nordea Bank Abp, Finland
Read more about the project
|